AmpliPhi Biosciencess C3J Logo

Armata has joined together two seasoned drug development teams, AmpliPhi Biosciences and C3J Therapeutics, to tackle the global and increasingly serious threat of antimicrobial-resistant bacterial infections. Driven by rigorous and innovative science, Armata is developing high-impact, best-in-class bacteriophage therapeutics with the potential to save millions of lives.

Armata Pharmaceuticals
Enter

Pipeline Overview

Armata’s phage product candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata’s lead product candidate, AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. Armata is also developing and advancing a broad pipeline of proprietary synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed with Merck.

divider
Pathogen Indications Discovery Preclinical Phase 1 Phase 2
Staphylococcus aureus Bacteremia
AP-SA01
Pseudomonas aeruginosa Respiratory
Undisclosed Undisclosed
Partnered
Merck
Pathogen
Indications
Phase Partner
S. aureus
Bacteremia
Phase 1/2
(AP-SA01)
P. aeruginosa
Respiratory
Preclinical
Undisclosed
Undisclosed
Discovery Merck